Biogen Inc (BIIB) to Spin Off Hemophilia Drug Business

May 3, 2016, 12:37 pm EDT

Biogen Inc (BIIB) has announced plans to spin off is hemophilia drug business.

BIIB’s plans would have its hemophilia drug business becoming its own publicly traded company. The objective of the plan is to create two different company’s that can both better focus on their goals and drive value for investors.

The new company being made from Biogen’s hemophilia drug business doesn’t have a name yet. It will have BIIB’s current Pharmaceutical Operations & Technology Executive Vice President John Cox as its CEO. Read 

Koninklijke Philips NV (ADR) IPO: World’s Largest Light Maker Plans Spinoff

May 3, 2016, 11:14 am EDT

Koninklijke Philips NV (ADR) (PHG) has announced plans for an IPO spinoff.

The Philips IPO would have the company selling 25% if its lighting business as it looks to better focus on its medical offerings. It’s the largest lighting company in the world and has the most patents in the industry.

Plans for the Philips IPO that would spinoff its lighting business started two years ago. The company said it was likely the spinoff would occur in its Q1 earnings report released last week. It plans to sell at least a 25% stake of the business on the Euronext Amsterdam as part of the IPO, reports Reuters. Read 

Intellia Therapeutics IPO: The “Biggest Biotech Discovery of the Century”

May 2, 2016, 2:58 pm EDT
Intellia Therapeutics IPO: The “Biggest Biotech Discovery of the Century”

By fits and starts, the market for initial public offerings is getting its footing. Of the four deals on tap this week, all are biotech operators. But among these offerings, there is one that is likely to stand out — Intellia Therapeutics.

Intellia plans to offer 5 million shares at a range of $16 to $18, and the lead underwriters include Credit Suisse Group AG (ADR) (CS), Jefferies and Leerink Partners. The proposed ticker stated in Intellia’s S1 form is NTLA.

The excitement for the IPO centers around Intellia’s Crispr-Cas9 technology, which is a naturally occurring defense mechanism in bacteria that fights against foreign DNA. Dr. Jennifer Doudna, a scientist at Berkeley, sees this as a way to potentially fight cancer and other diseases. Read 

The $68B Uber IPO Is DEFINITELY Not Worth the Wait

Apr 19, 2016, 10:00 am EDT

If you’ve been patiently anticipating Uber to go public, stop. It’s not coming this year, and it may not even hit the markets in 2017. Source: via Uber

In fact, just last month Uber CEO Travis Kalanick revealed in a CNBC interview that he’s trying to push Uber’s initial public offering back as far as possible, although he didn’t explicitly say why.

Well, allow me to offer up a theory: I think Uber’s delaying the inevitable IPO because it knows its private market valuation is insane — and ultimately won’t fly for very long on Wall Street. Read 

3 New Stocks to Watch This Week – MGP, ARA, SCWX

Apr 18, 2016, 2:43 pm EDT
3 New Stocks to Watch This Week – MGP, ARA, SCWX

It has been a long hibernation for IPOs, primarily because of the volatility in the markets. But now it looks like things are getting back to normal. Yes, there are three new stocks on tap for this week. Source: Flickr

If anything, there should be a hearty appetite for deals, as we got a glimpse of last week. Bats Global Markets Inc. (BATS), which operates an alternative market system for investors, pulled off a successful IPO, with the stock up 21% on Friday. The company bumped up the number of shares offered from 11.2 million to 13.3 million, which certainly was an indication of robust demand.

OK, so what are the new stocks for the week? Well, here’s a look at all of them: Read 

SecureWorks (SCWX): Get Ready for This Year’s First Tech IPO

Apr 6, 2016, 1:45 pm EDT
SecureWorks (SCWX): Get Ready for This Year’s First Tech IPO

There’s been little to write about in the IPO Playbook so far this year. But there’s good news — that should change soon with the first tech IPO of the year, SecureWorks (SCWX).

According to the Wall Street Journal, the company is gearing up for a roadshow next week. This means a SecureWorks deal is likely to come to market around April 20th to 22nd or so.

The lead underwriters include the who’s who of Wall Street, such as Bank of America Corp (BAC), Morgan Stanley (MS), Goldman Sachs Group Inc (GS) and JP Morgan Chase & Co. (JPM), among several others. The proposed ticker for SecureWorks is SCWX and the listing is planned for the Nasdaq exchange. Read 

1 2 3 4 5 242